Form 4: BridgeBio Pharma Executive Maricel Apuli Reports Stock Grant

Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, reports the acquisition of restricted stock units.

Summary

• On March 19, 2025, Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., was granted 23,660 restricted stock units (RSUs).
• These RSUs were granted under the company's 2021 Amended and Restated Stock Option and Incentive Plan.
• The RSUs will vest in installments of 1/16th of the underlying shares starting May 16, 2025, and then quarterly until fully vested, contingent upon continued service with the Issuer.
• Following this transaction, Apuli directly owns 148,665 shares of BridgeBio Pharma, Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the executive's continued service and the company's future.

Positives

• The grant of RSUs aligns the executive's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and commitment from the Chief Accounting Officer.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the RSUs.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies. It provides transparency regarding the equity-based compensation awarded to key personnel.

Stakeholder Impact

• Shareholders may view the RSU grant as a way to align management's interests with the company's long-term success.
• Employees may see this as a positive sign of investment in key personnel.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Maricel Apuli, Restricted Stock Units, RSUs, Stock Option Plan, Beneficial Ownership, Form 4, SEC Filing